2023
AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review
Garcia-Tsao G, Abraldes J, Rich N, Wong V. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review. Gastroenterology 2023, 166: 202-210. PMID: 37978969, DOI: 10.1053/j.gastro.2023.10.016.Peer-Reviewed Original ResearchConceptsSpontaneous bacterial peritonitisAcute kidney injuryLarge-volume paracentesisEffective arterial blood volumeVasoactive drugsVariceal hemorrhageArterial blood volumeHRS-AKIUncomplicated ascitesIntravenous albuminVolume statusPractice UpdateBlood volumeChronic liver failure grade 3Best practice advice statementsClinical Practice Updates CommitteeEnd-stage liver diseaseAGA Clinical Practice UpdateForms of AKIIntensive care unit monitoringAGA Governing BoardCombination of vasoconstrictorsInitial endoscopic hemostasisPatient's volume statusClinical Practice Update
2021
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases
Biggins SW, Angeli P, Garcia‐Tsao G, Ginès P, Ling SC, Nadim MK, Wong F, Kim WR. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021, 74: 1014-1048. PMID: 33942342, DOI: 10.1002/hep.31884.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2011
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1*
Boyer TD, Sanyal AJ, Garcia‐Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V, Sigal S, Bexon AS, Teuber P, Group T. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1*. Liver Transplantation 2011, 17: 1328-1332. PMID: 21837734, PMCID: PMC3760727, DOI: 10.1002/lt.22395.Peer-Reviewed Original ResearchMeSH KeywordsAlbuminsCohort StudiesHepatorenal SyndromeHumansLiver FailureLiver TransplantationLypressinPrognosisSurvival RateTerlipressinVasoconstrictor AgentsConceptsHepatorenal syndrome type 1Liver transplantationHepatorenal syndromeSyndrome type 1Nontransplant patientsTransplant patientsSurvival benefitSurvival rateType 1Pretransplant renal functionUse of terlipressinClear survival benefitCohort of patientsSurvival of patientsHRS reversalPosttransplant managementLiver transplantPosttransplant survivalMost patientsPosttransplant outcomesRenal functionPoor prognosisTerlipressinPatientsTransplantation
2010
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis
Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, Garcia‐Tsao G, Lee SS. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver International 2010, 30: 937-947. PMID: 20492521, DOI: 10.1111/j.1478-3231.2010.02272.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCirrhotic patientsHepatorenal syndrome type 2Transjugular intrahepatic portosystemic shuntEpisode of ascitesChronic renal insufficiencyLow sodium dietStandard medical treatmentIntrahepatic portosystemic shuntOccurrence of refractorinessCentral hypovolaemiaVasoconstrictor systemsArterial hypotensionDiuretic dosesLiver transplantationPortal hypertensionRefractory ascitesRenal insufficiencySodium dietSystemic haemodynamicsFrequent complicationSevere complicationsSerious complicationsSuch patientsPortosystemic shuntRenal sodium
2008
A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome
Sanyal AJ, Boyer T, Garcia–Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P, Group T. A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome. Gastroenterology 2008, 134: 1360-1368. PMID: 18471513, PMCID: PMC3730280, DOI: 10.1053/j.gastro.2008.02.014.Peer-Reviewed Original ResearchMeSH KeywordsDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesGermanyHepatorenal SyndromeHumansInjections, IntravenousKidney Function TestsLypressinMaleMiddle AgedProspective StudiesRussiaSeverity of Illness IndexShock, SepticSurvival RateTerlipressinTreatment OutcomeUnited StatesVasoconstrictor AgentsConceptsHRS type 1Type 1 HRSSCr levelsTreatment successDay 14Type 1Total adverse event rateType 1 hepatorenal syndromePlacebo-controlled clinical trialSafety of terlipressinTrial of terlipressinAdvanced liver diseaseFunctional renal failureNonfatal myocardial infarctionSerum creatinine levelsTransplantation-free survivalAdverse event ratesSyndrome type 1Arterial vasoconstrictorHepatorenal syndromeHRS reversalCreatinine levelsRenal failureRenal functionLiver disease
2001
CLINICAL MANAGEMENT OF ASCITES AND ITS COMPLICATIONS
Wongcharatrawee S, Garcia-Tsao G. CLINICAL MANAGEMENT OF ASCITES AND ITS COMPLICATIONS. Clinics In Liver Disease 2001, 5: 833-850. PMID: 11565143, DOI: 10.1016/s1089-3261(05)70194-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsEffective arterial blood volumeElimination of ascitesTherapy of ascitesPoor prognostic signYear mortality rateDevelopment of ascitesArterial blood volumeQuality of lifeSinusoidal hypertensionLiver transplantationCirrhotic patientsSurvival benefitLethal complicationPathophysiologic abnormalitiesPrognostic signSodium retentionCurrent therapiesAscites formationClinical managementAscitesBlood volumeMortality rateComplicationsTherapyHypertensionCurrent management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis
Garcia–Tsao G. Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001, 120: 726-748. PMID: 11179247, DOI: 10.1053/gast.2001.22580.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements